SiRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions
The invention relates to methods and compositions for the treatment and/or prevention of eye conditions related to high levels of expression and/or activity of the vanilloid-1 receptor (TRPV).
1. A method of treating dry eye and/or ocular pain in a subject in need thereof, said method comprising administering topically to the eye of the subject an siRNA having the sequence as set forth in SEQ ID NO: 2 and targeted to SEQ ID NO: 1, said siRNA administered at a dosage of 0.3 mg to 0.9 mg per day; wherein the dosage is effective in reducing dry eye and/or ocular pain in the subject undergoing treatment.
2. The method according to claim 1 , wherein the siRNA is administered for 5 to 15 days.
3. The method according to claim 1 , wherein the siRNA is administered for 10 days.
4. The method according to claim 1 , wherein the siRNA is administered chronically.
5. A unit dosage form for treating eye and/or ocular pain in a subject in need thereof, said dosage form comprising an siRNA having the sequence as set forth in SEQ ID NO: 2 and targeted to SEQ ID NO: 1 in a therapeutic amount of 0.3 mg to 0.9 mg, and a pharmaceutically acceptable carrier or diluent.
6. A kit for administering an siRNA having the sequence as set forth in SEQ ID NO: 2 and targeted to SEQ ID NO: 1, said kit comprising a dosage of the siRNA of 0.3 mg to 0.9 mg for daily administration, and printed instructions for administering the siRNA.
7. The method according to claim 1 , wherein the siRNA is administered at a dosage of 0.5 mg per day.
8. The unit dosage form according to claim 5 , wherein said unit dosage form comprises said siRNA in a therapeutic amount of 0.5 mg.
9. The kit according to claim 6 , wherein said kit comprises said siRNA in a dosage of 0.5 mg.
10. The method according to claim 7 , wherein the siRNA is administered for 5 to 15 days.
11. The method according to claim 7 , wherein the siRNA is administered for 10 days.
12. The method according to claim 7 , wherein the siRNA is administered chronically.
13. The method of claim 1 wherein the subject is human.
14. The method of claim 7 wherein the subject is human.